Methylenetetrahydrofolate reductase C677T gene polymorphism and prostate cancer risk

2Citations
Citations of this article
5Readers
Mendeley users who have this article in their library.

Abstract

Objective: The single nucleotide polymorphism C677T of the methylenetetrahydrofolate reductase (MTHFR) gene encodes a thermolabile enzyme. This polymorphism was found to be implicated in cancer susceptibility. In this study, we analyzed the distribution of the MTHFR C677T polymorphism in two cohorts; patients and controls native of East of Algeria to explore the possible association between this polymorphism and prostate cancer susceptibility. Methods: Our examination has been conducted in 98 cases and 98 healthy controls. Genotyping was realized by polymerase chain reaction-restriction fragment length polymorphism method. Results: Compared with CC homozygous, the CT heterozygous was found to have a significantly increased risk of prostate cancer (p=0.04; odds ratio [OR]=2.01, 95% confidence interval [CI]: 1.02–3.95). However, no statistically significant difference was observed concerning the TT homozygous (p=0.74; OR=1.25, 95% CI: 0.51–3.04). Conclusion: Our results indicate that the genotype CT is a risk factor for prostate cancer in East of Algeria.

Cite

CITATION STYLE

APA

Tellouche-Bouhouhou, S., Chellat-Rezgoune, D., Abadi, N., Satta, D., & Dahdouh, A. (2018). Methylenetetrahydrofolate reductase C677T gene polymorphism and prostate cancer risk. Asian Journal of Pharmaceutical and Clinical Research, 11(5), 387–389. https://doi.org/10.22159/ajpcr.2018.v11i5.24390

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free